[의학신문·일간보사=김정일 기자]Daewon Pharmaceutical’s squeezed cold medicine ‘Chol Daewon’ recorded a double-digit market share in the over-the-counter cold medicine market last year.
According to data from IQVIA, a pharmaceutical market research institute, the total sales of the cold category market last year were regarding 215.3 billion won, an increase of 77.5% from the previous year. The general cold medicine market has maintained a 100 billion won range from 135 billion won in 2019, 138 billion won in 2020, and 121.3 billion won in 2021.
Among them, Cole Daewon recorded sales of 23 billion won last year, up 272% from the previous year (an increase of 16.8 billion won). Call Daewon’s market share also increased significantly from regarding 5% in 2021 to 10.6% in 2022.
Cole Daewon’s position in the cold medicine market for children has also been strengthened. Last year, Cole Dae One Kids recorded sales of 9.2 billion won, a 252% increase compared to the previous year, and ranked first in the industry for the first time. This is the first achievement in 5 years since it first appeared on the market in 2017.
It is believed that this is because the demand for comprehensive cold medicine for children has increased while suffering from Corona 19, and the inclusion of Koldae One Kids in the health care set provided by the government to home care providers has also gained popularity through word of mouth. Sales of Cole Dae One Kids Cold, a comprehensive cold medicine in the Cole Dae One Kids series, jumped from 400 million won in 2021 to 2.1 billion won in 2022.
Recently, the brand was renewed from the existing Koldae One-S series to the Kol-dae One-Q series, which further improved the effect by changing the ingredients and content.
A company official said, “Although the number of patients with COVID-19 and flu has decreased significantly, the demand for cold medicine, which has become an essential household medicine in the home, will not fall easily.” This is the result of meeting this appropriate marketing strategy.”
